However, it was possible to distinguish a changing profile of intervention components across the patient treatment pathway covered in the included trials.
According to the profile of intervention costs set out by GMAP, there are four components to anti-malaria expenditure: prevention, case management (diagnosis and treatment), program costs (such as monitoring and evaluation, training, and infrastructure), and research and development expenses.
Based on our field studies, we produced 27 implementation profiles of interventions that were sufficiently developed to inform adoption, adaptation, and scale-up by colleagues involved in VMMC demand generation in eastern and southern Africa.
Indirect net risks arise when a research intervention has a favorable risk-benefit profile, but the intervention diminishes the risk-benefit profile of other interventions provided as part of or in parallel to the study.
This is consistent with the safety profile of epidural interventions demonstrated in the literature.
According to our best knowledge, the current study offers unique insight on the potentials of HCU databases to estimate the cost-effectiveness profile of medical interventions on osteoporosis.
*Bias would occur if specific harm had been measured, but data were presented or suppressed in a way that would mask the harm profile of particular interventions.
However, the complex flavonoid and phenolic profile of the interventions limited the ability to trace the metabolites back to their source.
Specifically, the risk benefit profile of pharmacological interventions should be considered to ensure that they do not compromise engagement with functional rehabilitation, as for example, the excessive drowsiness that can be seen with opioids.
In the context of harm outcomes, we awarded classifications for "high risk" outcome reporting bias when the specific harm had been measured but the data were presented or suppressed in a way that would mask the harm profile of particular interventions (including providing detail on the seriousness of the harms)—that is, P1, P2, R, and S classifications (table 1).
